Author: Ravi Shankar

Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab

FREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. The study shows that patients with early symptomatic Alzheimer’s disease exhibit markedly different biological responses during treatment with lecanemab.

Led by investigators at Washington University School of Medicine in St. Louis, the study used Alamar’s NULISAseq™ CNS 120 panel to measure 130 plasma proteins spanning amyloid and tau pathology, inflammation, neurodegeneration and synaptic function. Researchers profiled 2,385 samples from 1,967 participants using just 25 microliters of plasma per sample, including patients receiving lecanemab as part of standard clinical care at the Washington University Memory Diagnostic Center and untreated comparison groups from the Knight Alzheimer Disease Research Center.

“Anti-amyloid therapies are now part of routine care, but until now we have had a very narrow window into what is actually happening biologically in the patients receiving them,” said Carlos Cruchaga, PhD, Professor of Psychiatry and director of the NeuroGenomics and Informatics Center at Washington University School of Medicine, and co-senior author of the study. “Our findings show that Alzheimer’s disease and neurodegeneration biomarkers have unique trajectories that capture specific biological process associated with treatment response.”

The proteins associated with amyloid clearance were largely different from those associated with subsequent cognitive decline. The findings show that amyloid clearance and cognitive response reflect different biological processes, helping explain why clearing amyloid does not produce the same degree of clinical benefit in every patient, a pattern observed both in this cohort and across anti-amyloid trials.

Additionally, among 197 patients treated with lecanemab, 34 of the 130 biomarkers measured significantly changed with the number of infusions received, and they did not all move in the same direction. Among the proteins that most strongly distinguished these patients from controls, the brain-derived forms of tau consistently outperformed the same proteins circulating in the periphery, accounting for four of the top five both before treatment and at the last infusion stage. Separating tau that originates in the brain from its systemic counterpart requires both high specificity for the brain-derived form and the sensitivity to detect it at very low concentrations. Measuring these variants alongside more than 100 additional proteins in a single sample is what allowed the investigators to track pathology and treatment response in one assay.

“This study shows why measuring one or two biomarkers is not enough to understand what is happening during treatment and why ultra-high sensitivity matters,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “Alamar’s precision proteomics platform gives researchers a much richer picture of treatment response and helps us understand why patients with the same diagnosis can have very different outcomes.”

About Alamar Biosciences 
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com. 

Forward Looking Statements 
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the Alamar platform’s capabilities, performance and impact, including its ability to provide richer insights into the treatment response of patients receiving anti-amyloid antibody therapy in real-world clinical practice. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed with the SEC on , 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. 

Media Contact: 
Media@alamarbio.com 

Investor Contact: 
Investors@alamarbio.com 

PERTH, Australia, Sept. 24, 2026 (GLOBE NEWSWIRE) — FireFly Metals Ltd (ASX/TSX: FFM) (FireFly or the Company) advises, in accordance with ASX Listing Rule 3.13.1, that the Annual General Meeting (AGM) of the Company will be held on Tuesday, 24 November 2026.

Details of how shareholders can participate in the AGM will be provided with the Notice of Meeting to be released in due course.

An item of business at the AGM will be the election and re-election of directors. In accordance with article 7.5 of the Company’s Constitution, the closing date for receipt of nominations from persons wishing to be considered for election as a director is Tuesday, 6 October 2026.

Any nominations must be received at the Company’s registered office by 5:00pm (AWST) on Tuesday, 6 October 2026.

For further information regarding FireFly Metals Ltd please visit the ASX platform (ASX:FFM) or the Company’s website https://fireflymetals.com.au/.

Authorised by the Board of Directors.

Laura Noonan-Crowe
Company Secretary        
FireFly Metals Ltd

+61 8 9220 9030
info@fireflymetals.com.au
www.fireflymetals.com.au

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — MAK Acquisition Corp. (TSX: MAK.U) (“MAK”) announced today that it has delivered a notice of breach to Uni Express Inc. (“UniUni”) pursuant to the purchase agreement (the “Purchase Agreement”) among MAK and UniUni governing the proposed reverse take-over by MAK of UniUni (the “Proposed Transaction”). Pursuant to the terms of the Purchase Agreement, UniUni agreed to operate its business within certain specified parameters during the interim period, including a defined maximum cumulative pre-tax loss. Since the announcement of the Proposed Transaction, UniUni’s business and financial performance has deteriorated. MAK believes this constitutes a material breach of the Purchase Agreement.

The delivery of the notice of breach triggers a 15 business day cure period during which UniUni may cure the breach. If UniUni is unable to cure the breach within such period, MAK intends to exercise its rights to terminate the Purchase Agreement.

About MAK Acquisition Corp.

MAK is a special purpose acquisition corporation focused on niche-market businesses providing critical solutions, with strong revenue retention and diversified customer bases. MAK is an exempted company formed under the laws of the Cayman Islands. MAK completed its initial public offering in October 2025 and its securities are listed on the Toronto Stock Exchange under the symbols “MAK.U” and “MAK.WT”. For more information, visit www.makacquisitioncorp.com.

Forward-Looking Information

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “Forward-looking information”) within the meaning of applicable securities laws, including with respect to the Company’s qualifying acquisition. This forward-looking information is identified by the use of terms and phrases such as “may”, “would”, “should”, “could”, “expect”, “intend”, “estimate”, “anticipate”, “plan”, “foresee”, “believe”, or “continue”, the negative of these terms and similar terminology, including references to assumptions, although not all forward-looking information contains these terms and phrases. Economic and geopolitical uncertainties, including regional conflicts and wars, including potential impacts of sanctions, may also heighten the impact of certain factors described herein. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

Forward-looking information is based on management’s beliefs and assumptions and on information currently available to management. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, investors are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information.

Forward-looking information involves known and unknown risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, the risk that the strategic review process may not result in a transaction on suitable terms, or at all, and the other risk factors described in detail under “Risk Factors” of the Company’s final long form prospectus dated October 22, 2025 and the Company’s preliminary long form prospectus dated June 10, 2026.

Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein represents our expectations as of the date hereof or as of the date it is otherwise stated to be made, as applicable, and is subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

For further information, please contact:

Investor Relations Contact:

Ross Marshall
Phone: 416.526.1563
Email: ross.marshall@loderockadvisors.com

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to report the voting results from its Annual General Meeting of shareholders (the “Meeting”) held earlier today.

A total of 26,439,140 shares were represented in person or by proxy at the Meeting, constituting approximately 39.1% shares represented of the Company’s total issued and outstanding Common shares as of the record date, and voted in favour of all matters brought before the Meeting.

Results of Annual General Meeting

The following matters put forward before shareholders for consideration and approval as set out in Rubicon Organics’ management information circular dated August 19^th, 2026 (the “Circular”) were approved by the shareholders:

• Setting the number of directors of the Company at five;
• Electing Doris Bitz, Jesse McConnell, John Pigott, Margaret Brodie, and Michael Detlefsen as directors of the Company (together the “Board”) for the ensuing year until the next annual meeting of the Company; and
• Appointing PricewaterhouseCoopers LLP as the Company’s auditors for the ensuing year with the Company’s directors authorized to fix their remuneration.

Question	Yes		No		Abstain
Number of Directors at Five (5)	99.8%		0.2%		–
Elect as Director, Doris Bitz	99.2%		–		0.8%
Elect as Director, Jesse McConnell	98.7%		–		1.3%
Elect as Director, John Pigott	92.8%		–		7.2%
Elect as Director, Margaret Brodie	98.6%		–		1.4%
Elect as Director, Michael Detlefsen	93.6%		–		6.4%
Appointment of Auditor	100.0%		–		–

Board Departures

As Len Boggio, Ian Gordon, and Karen Proud did not stand for re-election at the Meeting, they have retired from the Board effective today.

“On behalf of Rubicon Organics and the Board, I would like to thank Len, Ian, and Karen for their dedicated service and valuable contributions to the Company,” said Doris Bitz, Chair of the Board. “Their guidance, experience, and commitment have supported Rubicon Organics through important stages of its development, and we wish each of them the very best in their future endeavours.”

Engagement of Atrium Research Corporation

Rubicon Organics has renewed the services of Atrium Research Corporation (“Atrium”), an independent third-party, to provide research services. Atrium will receive $10,500 per quarter for 12 months beginning on October 1st, 2026. This engagement is subject to TSX-V approval. Atrium and the Company are arm’s-length parties, and neither Atrium nor its insiders holds any shares or options to purchase shares in the issued and outstanding capital of the Company.

ABOUT RUBICON ORGANICS INC.

Rubicon Organics is the Canadian leader in certified organic and premium cannabis. With a vertically integrated model and strong national distribution, the company is scaling a house of trusted, high-performing brands including Simply Bare™ Organics, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™.

The Company operates two complementary cultivation facilities in British Columbia: the flagship 125,000 square foot Pacifica hybrid greenhouse in Delta and the 47,500 square foot Cascadia indoor facility in Hope. Cascadia is now fully planted and operational, contributing to Rubicon’s total current annual production capacity of approximately 15,500 kilograms of premium cannabis.

With proprietary genetics, award-winning products, and certifications enabling international distribution, Rubicon is positioned at the forefront of the premium cannabis segment.

As the Canadian market continues to evolve and global demand for high-quality cannabis increases, Rubicon Organics’ disciplined execution, brand equity, and consumer loyalty set it apart. The Company’s continued focus on premium quality, thoughtful innovation, and operational excellence has supported steady revenue growth and positive Adjusted EBITDA.

Rubicon Organics represents a rare combination of category leadership, operational strength, and long-term growth potential.

For more information visit www.rubiconorganics.com.

CONTACT INFORMATION

Margaret Brodie
Chief Executive Officer
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

The TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”. Forward-looking information can be identified by the use of words such as “will”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “may”, “could”, “would”, “should”, “estimates”, “potential” or variations of such words and similar expressions or statements that certain actions, events or results may, could, would, should or will, occur or be achieved.

Forward-looking information is based on management’s current expectations, estimates, projections and assumptions as of the date of this press release, including, without limitation, assumptions regarding the continued service and contributions of the directors elected at the Meeting; the Company’s ability to benefit from the experience and expertise of its Board; the Board’s ability to provide effective governance and strategic oversight; the continued availability of Atrium’s services on the terms described herein; stable market conditions; the Company’s ability to maintain product quality, supply and production levels; and the Company’s ability to successfully execute its business and international expansion strategies.

Forward-looking information in this press release includes, without limitation, statements regarding the contributions of the directors elected at the Meeting; the Board’s role in supporting the Company’s long-term objectives; the renewal of Atrium’s services for a 12-month period; the Company’s ability to expand its presence in regulated international markets; the expected benefits of new product launches; and the Company’s production capacity, revenue growth opportunities and strategic initiatives. These risks and uncertainties include, among others, the risk that anticipated production, yield, operational efficiency, revenue, margin or profitability targets are not achieved; changes in market conditions, consumer demand, competition, regulatory developments, access to capital; and the other risk factors described under the heading “Risk Factors” in Rubicon Organics’ Annual Information Form dated March 23, 2026, filed with the Canadian securities regulatory authorities.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the Company believes that the expectations and assumptions underlying such statements are reasonable, there can be no assurance that they will prove to be accurate, and actual results and future events may differ materially from those anticipated. Except as required by applicable law, Rubicon Organics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D., M.B.A., M.P.H., to the Company’s Board of Directors, effective immediately. The appointments bring together two accomplished leaders whose complementary experience spans public service, Medicare Advantage, clinical practice, healthcare policy, and business. Senator Torricelli will serve on the Board’s Audit Committee, and Dr. Miller will serve on its Clinical Committee. The appointments fill the Board’s two previously disclosed vacancies and bring the Board to nine directors.

“Today marks an exciting step forward for Clover, and we are thrilled to welcome Bob and Brian to our Board,” said Andrew Toy, Chief Executive Officer of Clover Health. “Bob brings deep ties to New Jersey communities, experience navigating federal policy, and firsthand knowledge of Clover. Brian combines clinical experience with a national perspective on Medicare payment and technology policy. His insights will help us advance care that improves quality, operates more efficiently, and generates meaningful savings. Together, their experience, judgment, and perspectives will strengthen our Board and reinforce our ability to execute with discipline, grow responsibly, and build lasting value for our members, physicians, and shareholders.”

“From the beginning, we built Clover around the belief that some of the hardest problems in healthcare can be solved by challenging long-held assumptions about how healthcare works and care is delivered,” added Vivek Garipalli, Co-founder of Clover Health and Executive Chairperson of the Board. “As Clover grows, it is important that our Board continues to reflect the complexity of the healthcare system we are working to improve and brings together special individuals who understand it from fundamentally different vantage points. Bob and Brian add tremendous depth across public policy, medicine, Medicare and business, and their perspectives will be invaluable as we drive forward on Clover’s mission to Improve Every Life.”

Senator Torricelli brings a distinctive combination of deep New Jersey roots, national policymaking experience, and firsthand knowledge of Clover. For 20 years, he represented New Jersey in the U.S. House of Representatives and the U.S. Senate, where his committee service included the Senate Finance Committee and work on federal financing for healthcare institutions. Following his congressional career, he founded Rosemont Associates, a business strategy firm, and established Woodrose Properties, a real estate development business. Since 2022, he has served on the board of the Company’s insurance subsidiaries, giving him firsthand familiarity with Clover’s business, mission, and approach to Medicare Advantage. Additionally, Senator Torricelli has served as a director of Glassbridge Enterprises, Inc. since February 2017 and previously served as executive vice president and chief operating officer of Aveta, Inc., a healthcare services company. His experience navigating complex policy and business issues will bring a valuable perspective to Clover’s Board and Audit Committee.

“Through my years living in New Jersey and representing its communities in Congress, I have come to know the challenges many seniors face in accessing high-quality, affordable care,” said Senator Torricelli. “Through my service on Clover’s insurance subsidiary board, I have seen the Company’s commitment to meeting those challenges with an ambitious vision and a practical, technology-driven approach. I am honored to join the Board and excited to contribute to its oversight, support this talented team, and help Clover build lasting value for members and shareholders.”

Dr. Miller brings a rare combination of frontline clinical practice and national Medicare policy leadership. A practicing hospitalist at the Johns Hopkins Hospital, an Associate Professor of Medicine at the Johns Hopkins University School of Medicine and Visiting Fellow at the Hoover Institution, Dr. Miller brings to Clover broad ranging regulatory experience spanning the Centers for Medicare & Medicaid Services, the U.S. Food and Drug Administration, and the Federal Trade Commission. He currently serves as Vice Chairman of the Board of Trustees for the North Carolina State Health Plan and as a Commissioner on the Medicare Payment Advisory Commission (MedPAC), the independent, nonpartisan commission that advises Congress on Medicare payment policy. Board-certified in internal medicine and preventive medicine, Dr. Miller offers a practical perspective on improving care delivery and advancing a more effective Medicare program.

“As a practicing physician, I see every day how much better technology can support clinical practice when it delivers the right information at the point of care,” said Dr. Miller. “Medicare needs models that can improve both convenience and quality for consumers, increase efficiency, and generate savings without adding burden for physicians or patients. Clover is building a differentiated model for Medicare Advantage: flexible and nimble, powered by technology, and close enough to physicians and patients to translate innovation into action. I am delighted to join the Board and look forward to helping Clover advance this approach and deliver a better care experience for people on Medicare.”

About Clover Health

Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health’s Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — PEDEVCO Corp. (NYSE American: PED) (“PEDEVCO” or the “Company”), a domestic energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region, today announced that its Interim President, Chief Executive Officer R.T. Dukes and Chief Financial Officer Robert Long, will participate in two upcoming virtual conferences hosted by Lytham Partners and Noble Capital Markets.

Lytham Partners Investor Conference – Fall Event | September 29 – 30, 2026

Management is scheduled to present on Tuesday, September 29, at 12:00 p.m. ET and will host virtual one-on-one meetings with investors on Wednesday, September 30, 2026. Interested parties can register for the event here or view the live presentation by visiting the conference webcast link here.

Noble Capital Markets Emerging Growth Virtual Equity Conference | October 1 – 2, 2026

Management is scheduled to present on Thursday, October 1, 2026, at 10:30 a.m. ET, and will host one-on-one meetings with investors that day. Interested parties can register on Noble’s website at www.nobleconference.com/virtual.

To request a meeting with PEDEVCO’s management team during the conferences, please contact your conference representative or the Company’s investor relations team at PED@elevate-ir.com. After each event, replays of the Company’s presentations will be listed in the investor relations section of its website at www.pedevco.com.

About PEDEVCO Corp.
PEDEVCO Corp. (NYSE American: PED) is a publicly traded energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region. The Company holds over 300,000 net acres, with principal assets in the D-J Basin of southeastern Wyoming and northern Colorado, as well as the Powder River Basin of northeastern Wyoming. PEDEVCO is headquartered in Houston, Texas. More information about PEDEVCO can be found at www.pedevco.com.

Media Contact:
PEDEVCO Corp.
(713) 221-1768
PR@pedevco.com

Investor Relations Contact:
Sean Mansouri, CFA or Laurent Weil
Elevate IR
(720) 330-2829
PED@elevate-ir.com

22^nd Century Group Calls on HHS Secretary Kennedy, Acting FDA Commissioner Diamantas and CTP Director Koplow to Enact and Implement the Reduced Nicotine Content Standard

Administration’s Reported Move to Accelerate Vape and Nicotine Pouch Authorizations Addresses Only Part of the Continuum of Risk

MOCKSVILLE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today called on political leaders and the U.S. Food and Drug Administration (“FDA”) to enact and implement the proposed “Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products,” 90 Fed. Reg. 5032 (Jan. 16, 2025) (“Proposed Rule”), which remains pending more than eight years after the FDA first announced its intent to act and more than a year after the public comment period closed.

The Company’s call follows a Wall Street Journal report published Wednesday that the Trump administration plans to change federal rules to speed the authorization of tobacco products such as flavored vapes and nicotine pouches, with the FDA expected to announce in coming days that it will revisit the 2021 rule governing premarket review of new tobacco product applications (“U.S. Regulators Plan Major Move to Speed Authorizations of Vapes, Tobacco Pouches,” WSJ, Sept. 23, 2026). 22nd Century supports those efforts and believes they represent only one component of a comprehensive continuum-of-risk strategy to address the harms of tobacco.

The Proposed Rule would establish a maximum nicotine level of 0.70 milligrams per gram of total tobacco in cigarettes, cigarette tobacco, roll-your-own tobacco, most cigars and pipe tobacco, a level low enough to no longer create or sustain addiction. The FDA first issued an advance notice of proposed rulemaking on the subject on March 16, 2018 (83 Fed. Reg. 11818). The Proposed Rule was issued on January 15, 2025, and the comment period closed on September 15, 2025. To date, there is no final rule, no published timeline and no public update from the agency.

What 22nd Century Is Asking Of Federal Policymakers

1. HHS Secretary Kennedy: Direct FDA to prioritize the pending standard, consistent with your stated commitment to tobacco harm reduction and to delivering results for the American people.
2. Acting FDA Commissioner Diamantas: Place the rule back on the FDA’s entry into the Unified Agenda and establish a clear timeline for transmitting a final rule.
3. CTP Director Koplow: Convene the Tobacco Products Scientific Advisory Committee (TPSAC) to review the standard, as FDA stated it intended to do, and complete that step publicly.
4. The Trump Administration: Clear interagency and OMB review rather than allowing the rule to remain undecided and apply the same acceleration to combusted products that it is applying to non-combusted alternatives and to make mandatory that all retailers that sell combustible cigarettes immediately make available, space on their shelves to carry VLNC products.
5. Congress: Members of the Senate Health, Education, Labor and Pensions Committee and the House Energy and Commerce Committee, from both parties, should request a status update from FDA and hold the agency to the 180-day review framework Congress established in the Tobacco Control Act of 2009. Senators who have consistently championed tobacco policy, including Senators Durbin and Merkley, have pressed the agency on the youth implications of its recent flavor decisions; that same scrutiny should extend to finishing a standard FDA itself projects would prevent 48 million young Americans from starting to smoke.

22nd Century notes that the standard is not a partisan question. The policy has been advanced under multiple administrations in both parties since 2009, and the FDA’s own analysis describes it as among the most consequential public health actions available to the agency.

The Evidence Is Irrefutable and the Tool Already Exists

“The evidence is irrefutable, and it has been for years. The FDA’s own scientists have modeled a standard that would prevent approximately 48 million young Americans from starting to smoke and avert 1.8 million tobacco-related deaths by 2060. That proposal and comment period have now been closed for more than one year, while cigarettes remain the leading cause of preventable death in this country. I am asking Secretary Kennedy, Acting Commissioner Diamantas and Director Koplow to finish the job, and I am asking Republicans and Democrats in Congress to insist on a timeline. A reduced nicotine content standard is not a competing policy to the administration’s vape and nicotine pouch efforts, it is the other half of the same objective. Accelerated authorizations for lower-risk alternatives help adults who want to move away from cigarettes; reducing nicotine in combusted products to non-addictive levels helps the adults who are still smoking make that move or quit altogether. Together, those two policies move people down the continuum of risk at population scale, and separately, neither reaches its potential. This is the single most powerful tool available under existing law to accomplish the objectives Washington says it wants, and it can be implemented with products that are already authorized, already in the market and already proven. The mandate should also include a mandatory allocation of space to allow a wider distribution of VLNC products in the combustible space in retail. The only barrier left is the willingness to move forward.” said Larry Firestone, Chief Executive Officer.

Based on the FDA’s population health model published with the Proposed Rule, adopting the standard would:

• Prevent approximately 48 million U.S. youth and young adults from starting to smoke by 2100;
• Prompt more than 12.9 million people who smoke to stop within one year of the rule taking effect, rising to 19.5 million within five years;
• Avert 1.8 million tobacco-related deaths by 2060, rising to 4.3 million by the end of the century;
• Deliver estimated benefits of more than $1.1 trillion per year over the first four decades.

The Proposed Rule bans no product. It caps nicotine — the substance that creates and sustains addiction — and leaves every product category legal, while expressly excluding e-cigarettes, nicotine pouches, heated tobacco products, smokeless tobacco, waterpipe tobacco and premium cigars.

The Technology Is Commercialized, Authorized and Ready

22nd Century’s proprietary non-GMO reduced nicotine tobacco plants are grown using patented technologies that regulate alkaloid biosynthesis, producing tobacco with 95% less nicotine than traditional tobacco. The Company’s VLN^® cigarettes are the only low nicotine combustible cigarettes authorized by the FDA in the United States, carrying authorized claims including “95% less nicotine,” “Helps reduce your nicotine consumption” and “Greatly reduces your nicotine consumption.”

As the Company stated in its comments filed in support of the Proposed Rule, the development and FDA authorization of very low nicotine content tobacco makes it entirely feasible to produce conventionally flavored, consumer-acceptable combusted tobacco products that deliver a customary smoking experience with greatly reduced nicotine levels that comply with the proposed standard. 22nd Century’s wholly owned subsidiary, a leading cigarette manufacturer, produces all VLN^® products at its 60,000 square foot facility in Mocksville, North Carolina, which has the capacity to produce more than 45 million cartons of combusted tobacco products annually, with additional space for expansion.

The Company is also the sole holder of an FDA-authorized reduced nicotine content combustible cigarette in the United States, and in May 2026 the FDA filed for scientific review of the Company’s modified risk tobacco product renewal applications for VLN^® King and VLN^® Menthol King cigarettes and opened a public docket.

Media Availability

Larry Firestone, Chairman and Chief Executive Officer, is available for interviews on the reduced nicotine content standard, the continuum of risk, and the Company’s FDA-authorized VLN^® products. To arrange an interview or request data or background materials, contact investorrelations@xxiicentury.com.

About 22nd Century Group, Inc.

22nd Century Group is pioneering the Tobacco Harm Reduction and Nicotine Reduction Movements by enabling smokers to take control of their nicotine consumption.

Our Technology is Tobacco

Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our-high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

Our Products

We created our flagship product, the VLN^® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN^® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

VLN^® and Helps You Smoke Less^® are registered trademarks of 22nd Century Limited LLC.

Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

Learn more about VLN^® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our expectations regarding regulatory enforcement, including our ability to receive authorization or approval for new products, and (ii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026 and Quarterly Reports on Form 10-Q filed May 7, 2026 and August 14, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact  
Daniel Otto
Chief Financial Officer & Investor Relations
22nd Century Group
investorrelations@xxiicentury.com

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Euro Sun Mining Inc. (TSX: ESM) (“Euro Sun” or the “Company”) is pleased to announce that it has closed its previously announced non-brokered US$3 million strategic equity investment by Urion Investments Holdings Limited (“Urion”), a Trafigura Group company (the “Investment”). For more information about the Investment, please see the Company’s press release dated September 3, 2026, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca.

Pursuant to the Investment, Euro Sun issued 21,974,210 units (each, a “Unit”) at a price of C$0.19 per Unit for gross proceeds of US$3,000,000 (approximately C$4,175,100). Each Unit consists of one common share of the Company (each, a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant shall be exercisable to acquire one Common Share at a price of C$0.40 per share until September 24, 2030.

The Units were issued pursuant to Ontario Securities Commission Rule 72-503 Distributions Outside Canada and are not subject to a hold period. The listing of the Common Shares and Warrants issued pursuant to the Investment remains subject to the final approval of the Toronto Stock Exchange. No finder’s fees were paid in connection with the Investment. The net proceeds of the Investment are expected to be used for the Rovina Valley Project and general corporate purposes.

In connection with the Investment, Euro Sun and Trafigura Pte Ltd. also entered into an amendment to the binding offtake agreement dated July 10, 2025, as amended and restated December 15, 2025 (the “Offtake Agreement”) to (among other things) provide for an offtake volume of 40% effective upon closing of the Investment. For more information about the Offtake Agreement, please see the Company’s press release dated July 10, 2025, a copy of which is also available under the Company’s SEDAR+ profile at www.sedarplus.ca.

About Euro Sun Mining Inc.

Euro Sun is a Toronto Stock Exchange-listed mining company focused on the exploration and development of its 100%-owned Rovina Valley Project located in west-central Romania, which hosts the second largest copper & gold deposit in Europe. Already granted European strategic status, the Rovina Valley Project is expected to unlock much needed investment and job creation in Hunedoara County and will deliver critical minerals necessary for Europe’s green energy transition.

Further information:

For further information about Euro Sun, or the contents of this press release, please contact Investor Relations at info@eurosunmining.com.

Caution regarding forward-looking information:

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the Investment, such as in respect of the Company’s intended use of net proceeds, receipt of final approval of the Toronto Stock Exchange, and other matters related thereto. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions. Investors are cautioned that forward-looking information is not based on historical facts but instead reflect management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, including: the risk that necessary approvals, including Toronto Stock Exchange approval, may not be obtained; general business, economic, competitive, political and social uncertainties in Romania and the European Union; future commodity prices and market demand; accidents, labour disputes and shortages; risks inherent in the mining industry; and other risks described in the Company’s public disclosure. Undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. This information is qualified in its entirety by cautionary statements and risk factor disclosure contained in filings made by the Company with the Canadian securities regulators, including the Company’s annual information form, financial statements and related MD&A for the financial year ended December 31, 2025, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

MONTREAL, Sept. 24, 2026 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14, August 27 and September 10, 2026, the Company voluntarily applied for and the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the year ended March 31, 2026, including the related management’s discussion and analysis, and Chief Executive Officer and Chief Financial certifications on or before July 29, 2026 (collectively the “Annual Financial Filings”). The deadline has been extended to on or before September 28, 2026.

Pursuant to the MCTO, the Chief Executive Officer and the Chief Financial Officer of the Company may not trade in securities of the Company until such time as the Company files its Annual Financial Filings on or before September 28, 2026, and the Executive Director of the BCSC revokes the MCTO. The MCTO does not affect the ability of shareholders to trade their securities.

The Company expects to file on or before September 28, 2026.

The Company confirms that it will continue to satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases until the time it has filed the Annual Financial Filings. The Company confirms that there is no other material information relating to its affairs that has not been generally disclosed.

For further information, please contact:
Jean Gosselin, CFO
Phone: (514) 394-7717
Email: info@prime-group.ca

Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations (including negative and grammatical variations) of such words and phrases or statements that certain acts, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements are based upon assumptions that are subject to significant risks and uncertainties, including risks regarding market conditions, general economic factors and the equity markets generally. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance of Prime may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although Prime believes that the expectations reflected in forward-looking statements are reasonable, they can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, Prime disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Manpower Outsourcing Revenue Increased 62.4% to US$15.6 Million; Integrated Facility Management Revenue Increased 11.1% to US$16.1 Million

Net Loss Narrowed 13.8% Year Over Year

Working Capital Improved to US$11.9 Million from a Deficit of US$1.7 Million at Year-End 2025; Total Liabilities Reduced 39%

SINGAPORE, Sept. 24, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (Nasdaq: YFOR) (“YYForce” or the “Company,” formerly YY Group Holding Limited (Nasdaq: YYGH)), an AI-enabled workforce management platform and integrated facility management (IFM) provider operating across Asia and beyond, today announced its unaudited financial results for the six months ended June 30, 2026.

YYForce reported first-half 2026 revenue of approximately US$32.7 million, an increase of 26.8% from US$25.8 million for the corresponding period in 2025. The Company views the continued expansion of its workforce and IFM businesses as the operating foundation for its “YYForce 2030 Vision,” a long-term strategy to build an integrated workforce ecosystem connecting human workers, artificial intelligence (“AI”), humanoid robots and specialized service robotics.

First Half 2026 Highlights

• Revenue increased 26.8% year over year to US$32.66 million from US$25.75 million.
• Manpower outsourcing revenue increased 62.4% year over year to US$15.55 million.
• IFM revenue increased 11.1% year over year to US$16.06 million.
• Gross profit was US$3.30 million and gross profit margin was 10.1%, compared with US$4.27 million and 16.6%, respectively, in the prior-year period, with the decrease primarily attributable to higher labor costs.
• Operating loss narrowed 32.2% year over year to US$5.21 million from US$7.68 million, primarily reflecting the absence of a US$4.06 million impairment loss on intangible asset recognized in the prior-year period.
• Operating loss as a percentage of revenue improved to 15.9% from 29.8% in the prior-year period.
• Net loss narrowed 13.8% year over year to US$7.06 million from US$8.20 million.
• Non-IFRS operating loss was approximately US$2.74 million and non-IFRS loss was approximately US$3.29 million.
• Cash was approximately US$3.08 million as of June 30, 2026.
• Total equity increased to approximately US$25.36 million from US$13.61 million as of December 31, 2025, primarily reflecting US$18.55 million in proceeds from the Company’s At-The-Market equity offering.
• Total liabilities decreased to approximately US$12.66 million from US$20.73 million as of December 31, 2025, primarily reflecting the settlement of trade and other payables and the reduction of warrant liabilities.

First Half 2026 Operational Highlights:

		For the Six Months Ended June 30,
		2026			2025
Manpower Services
YY Circle App downloads (cumulative)		998,575			586,389
YY Circle App monthly active users		35,743			30,103
Job fulfillment rate		92%			93%
Number of Employers		212			203
IFM Services
Number of customers		218			190
Average revenue per customer		73,682			76,095

Management Commentary

Mike Fu, CEO of YYForce, commented: “We delivered year-over-year revenue growth of 26.8% in the first half of 2026, led by a 62.4% increase in manpower outsourcing revenue and continued expansion of our IFM operations. Beyond scaling our existing service businesses, we are laying the foundation for building a future workforce environment in which people, artificial intelligence, smart facilities, automation and robotics can increasingly work together. We are piloting service robots and plan to deploy our first agentic AI workflows and launch an AI training data lab — early steps toward operations where every task is carried out by the person or technology best suited to perform it. Meanwhile, our growing workforce and IFM operations provide the customer relationships, workforce infrastructure, facilities and real operating environments we need to validate and commercialize these technologies. As we move toward 2030, we expect YYForce to evolve from a labor-intensive service provider toward an integrated workforce service provider ready for the future, focusing on margin improvement, operating efficiency and disciplined capital allocation to create value for our stakeholders.”

Jason Phua, CFO of YYForce, added, “This period’s revenue growth came with margin pressure. Hourly wages for casual workers rose faster than our billing rates. As a result, our gross profit margin narrowed to 10.1% from 16.6%. We are addressing this directly: repricing contracts as they come up for renewal, renegotiating or exiting engagements that no longer cover their cost, tightening scheduling to reduce unbilled hours, and evaluating technology-enabled, digital and automation solutions to improve productivity. We also improved our capital structure and working capital position, ending the half with working capital of US$11.9 million compared with a deficit at the end of 2025, and reducing total liabilities by 39%. Restoring gross profit margin is our priority for the second half of 2026, and we will report our progress with our full-year results.”

First Half 2026 Financial Results

Total Revenue was US$32.7 million in the first half of 2026, up 26.8% from US$25.8 million in the same period of 2025.

• Revenue from manpower outsourcing increased 62.4% to US$15.55 million from US$9.58 million in the same period of 2025. The increase was primarily attributable to stronger customer demand in Singapore and Malaysia and contributions from our Hong Kong and Thailand subsidiaries.
• Revenue from IFM increased 11.1% to US$16.06 million from US$14.46 million in the same period of 2025. Growth was supported by new contract wins, renewals of existing projects and full-period contributions from subsidiaries acquired in 2025, including Property Facility Services Pte. Ltd. and Uniforce Security Services Pte. Ltd.

Gross profit was approximately US$3.30 million, compared with US$4.27 million for the first half of 2025. Gross profit margin was approximately 10.1%, compared with 16.6% in the prior-year period. The decrease was principally attributable to higher labor costs across the Company’s IFM and manpower outsourcing businesses, including higher hourly wage rates for casual workers.

Operating loss decreased 32.2% to approximately US$5.21 million, compared with US$7.68 million in the corresponding period in 2025, primarily reflecting the absence of the US$4.06 million impairment loss on intangible asset recognized in the first half of 2025. Operating loss as a percentage of revenue improved to approximately 15.9%, compared with 29.8% for the corresponding period in 2025.

Net loss decreased 13.8% to approximately US$7.06 million, compared with US$8.20 million in the prior-year period. Basic and diluted loss per ordinary share was US$13.62, compared with US$311.00 in the first half of 2025. All share and per-share amounts have been retroactively adjusted to reflect the 50-for-1 and 30-for-1 reverse share splits effected on March 23, 2026 and June 23, 2026, respectively. First-half 2026 results also included a US$2.62 million net loss related to convertible notes and a US$1.73 million net gain related to warrant liabilities.

Net cash used in operating activities was approximately US$10.99 million for the first half of 2026, compared with US$0.63 million in the prior-year period, primarily reflecting the operating loss and the settlement of trade and other payables.

During the first half of 2026, net cash provided by financing activities was approximately US$16.29 million. Financing inflows included approximately US$18.55 million from the issuance of Class A ordinary shares in connection with the Company’s At-The-Market equity offering and proceeds from other financing activities.

YYForce intends to maintain a disciplined approach to capital allocation as it balances working-capital requirements, existing operations and investments supporting future growth.

YYForce 2030 Vision and Capital Allocation Strategy

On September 22, 2026, YYForce announced its 2030 Vision, its long-term roadmap for building a Future Workforce Solutions model integrating human workforce capabilities, AI-enabled workforce management, smart facility management technologies, automation and robotics. The plan builds on the Company’s existing businesses: YY Circle and Yolara AI applications for on-demand staffing and workforce solutions, humanoid and specialized service robotics offered through leasing and Robotics-as-a-Service (“RaaS”) arrangements, and smart facility management solutions through its 24iFM platform, IoT devices, sensors, smart cameras and automation technologies. Yolara AI is intended to support deployment planning, workflow integration, human-team coordination and ongoing operational support across these solutions. These AI, automation and robotics initiatives did not contribute materially to revenue during the six months ended June 30, 2026.

YYForce’s first capital allocation priority is maintaining sufficient liquidity for its existing operations, working capital needs and contractual obligations. Subject to these requirements, the Company may evaluate investments across workforce and smart facility management technology, software development, operational automation, commercial robotics, data infrastructure, geographic expansion, strategic partnerships and acquisitions. The Company expects to use partnerships, leasing arrangements and customer pilot programs to limit upfront capital commitments, and will evaluate each investment based on customer demand, technology readiness and expected returns.

FY2026 Guidance

In light of labor cost pressures in the first half of 2026, the Company is withdrawing the fiscal year 2026 outlook it issued on March 12, 2026. The Company expects to provide an updated outlook with its full-year 2026 results. Investors should no longer rely on the previously announced projections as representing the Company’s current expectations.

About YYForce Inc.

YYForce Inc. (Nasdaq: YFOR) is an AI-enabled workforce management platform and IFM provider, headquartered in Singapore and operating across Asia and beyond. The Company’s intelligent workforce solutions platform, YY Circle, helps clients across hospitality, food and beverage, retail, and other service sectors predict, plan, and optimize workforce deployment. In YYForce’s IFM business, its 24iFM software platform and comprehensive IFM subsidiary portfolio support clients across hospitality, transportation, banking, retail, and mixed-use facilities.

As both business lines scale, the Company is systematically embedding AI and automation capabilities – progressing from intelligent decision support toward increasingly autonomous workforce management – to improve service quality, reduce deployment costs, and drive long-term margin expansion. Listed on the Nasdaq Capital Market, YYForce is committed to infrastructure innovation, measurable client outcomes, and long-term value creation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, among other things, statements regarding YYForce’s 2030 Future Workforce Vision; future operating and financial performance; margin improvement; operating efficiency; cash generation; technology development; artificial intelligence; digital platforms; smart facility management; automation and robotics; potential humanoid-robot applications; geographic expansion; acquisitions; strategic partnerships; capital allocation; recurring-revenue opportunities; and future commercialization of new products and services.The Company bases these forward-looking statements on its expectations and projections about future events, which the Company derives from the information currently available to it. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. Forward-looking statements involve inherent risks and uncertainties, and the forward-looking events discussed in this press release may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about the Company and a number of factors. These factors include, but are not limited to, the Company’s goals and strategies; the Company’s future business development, financial condition and results of operations, including the introduction of new products and services, expected changes in the Company’s revenues, costs and expenditures, anticipated customer growth, and demand for and market acceptance of the Company’s products and services; and industry, market and regulatory conditions, including competition, government policies and regulations affecting the Company’s industry, and other factors that may affect the Company’s financial condition, liquidity and results of operations. For a more detailed discussion of risk factors, please refer to the Company’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s most recent annual report on Form 20-F, as amended.

Non-IFRS Financial Measures 

The Company uses non-IFRS measures such as non-IFRS net loss/profit in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that non-IFRS financial measures help identify underlying trends in the Company’s business that could otherwise be distorted by the effect of certain expenses that the Company includes in its results for the period. The Company believes that non-IFRS financial measures provide useful information about its results of operations, enhance the overall understanding of its past performance and future prospects, and allow for greater visibility with respect to key metrics used by its management in its financial and operational decision-making. Non-IFRS financial measures have limitations as analytical tools and should not be considered in isolation or construed as an alternative to IFRS financial measures or any other measure of performance or as an indicator of its operating performance.

The Company’s non-IFRS measures exclude consultancy fees, convertible notes related expenses, one-time accounting adjustments, and changes in the fair value of convertible notes and warrant liabilities. The complete reconciliation is presented below. Investors are encouraged to review the reconciliation together with the Company’s IFRS financial statements and not rely on any single financial measure. Non-IFRS financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company’s data. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. 

For more information on the Company’s non-IFRS financial measures, please see the section titled “Unaudited Reconciliation of IFRS and non-IFRS financial measures.” 

Investor Contact

Jason Zhi Yong Phua, Chief Financial Officer
YYForce Inc.
enquiries@yyforce.ai

Unaudited Reconciliation of IFRS and Non-IFRS Financial Measures

US$	Six months ended June 30, 2026 (Unaudited)		Six months ended June 30, 2026 (Unaudited) Non-IFRS reconciliation
Revenue	32,659,236		32,659,236
Cost of revenue	(29,359,389	)	(29,008,975	)
Gross profit	3,299,847		3,650,261
Other income	703,883		703,883
Selling and marketing expenses	(1,152,522	)	(652,522	)
General and administrative expenses	(7,902,969	)	(6,286,830	)
Other expenses	(111,423	)	(111,423	)
Change in fair value of investment properties	(44,079	)	(44,079	)
Operating loss	(5,207,263	)	(2,740,710	)
Finance cost	(865,273	)	(452,773	)
Net loss on convertible notes designated at FVTPL	(2,617,807	)	–
Net gain on warrant liabilities	1,726,802		–
Loss before tax	(6,963,541	)	(3,193,483	)
Income tax expenses	(99,272	)	(99,272	)
Loss for the period	(7,062,813	)	(3,292,755	)
Foreign currency translation differences – foreign operations	(817,032	)	(817,032	)
Change in fair value of convertible notes designated at FVTPL due to own credit risk	1,726		1,726
Total comprehensive loss for the period	(7,878,119	)	(4,108,061	)
Loss attributable to:
Non-controlling interests	108,080		108,080
Equity owners of the Company	(7,170,893	)	(3,400,835	)

Reconciliation of Non-IFRS to IFRS Loss Attributable to Equity Owners

Loss attributable to equity owners of the Company – non-IFRS	(3,400,835	)
Consultancy fees	(1,297,331	)
Convertible notes related expenses	(1,052,500	)
Net loss on convertible notes designated at FVTPL	(2,617,807	)
Net gain on warrant liabilities	1,726,802
One-time accounting adjustments	(529,222	)
Loss attributable to equity owners of the Company – IFRS	(7,170,893	)

YYFORCE INC. AND ITS SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

		Note		June 30, 2026 (Unaudited)				December 31, 2025
				$				$
Assets
Current assets:
Cash					3,082,570				1,511,760
Trade receivables, net		4			11,063,513				12,138,342
Prepayment and other current assets		5			4,373,945				1,251,794
Amount due from related parties		18			4,054,010				501,637
Total current assets					22,574,038				15,403,533
Non-current assets:
Right-of-use assets		6			1,254,966				1,463,494
Intangible assets, net		8			5,017,595				5,174,257
Investment properties		9			2,381,942				2,445,292
Net investment in lease		10			–				2,970,685
Property and equipment, net		7			579,025				527,092
Financial assets measured at fair value through profit or loss (“FVTPL”)					100,000				–
Prepayment and other non-current assets		5			179,151				422,849
Goodwill		8			5,808,574				5,808,574
Deferred tax assets					125,825				125,825
Total non-current assets					15,447,078				18,938,068
Total assets					38,021,116				34,341,601
Current liabilities:
Trade and other payables		11			4,572,651				10,837,525
Contract liabilities					572,280				–
Amount due to related parties		18			189,696				503,007
Lease liabilities, current		13			411,619				429,634
Convertible notes designated at FVTPL		12			14,379				–
Loans and borrowings, current		13			4,937,830				5,375,362
Total current liabilities					10,698,455				17,145,528
Non-current liabilities:
Loans and borrowings, non-current		13			367,687				627,526
Warrants liabilities		12			17,733				1,213,340
Deferred tax liabilities		17			645,722				645,722
Lease liabilities, non-current		13			928,611				1,099,767
Total non-current liabilities					1,959,753				3,586,355
Total liabilities					12,658,208				20,731,883
Equity
Share Capital*		14			43,966,842				24,825,837
Reserves		14			10,862,760				11,182,357
Accumulated deficit					(32,882,003	)			(25,711,110	)
Equity attributable to owners of the Company					21,947,599				10,297,084
Non-controlling interests					3,415,309				3,312,634
Total equity					25,362,908				13,609,718
Total liabilities and equity					38,021,116				34,341,601

*

The shares and per share information are presented on a retroactive basis to reflect the reorganization.

YYFORCE INC. AND ITS SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE (LOSS) INCOME

				For the six months ended June 30,
		Note		2026 (Unaudited)				2025 (Unaudited)
				$				$
Revenue		16			32,659,236				25,754,473
Cost of revenue		16			(29,359,389	)			(21,486,338	)
Gross profit					3,299,847				4,268,135
Other income		16			703,883				814,457
Selling and marketing expenses		16			(1,152,522	)			(1,562,277	)
General and administrative expenses		16			(7,902,969	)			(7,107,000	)
Impairment loss on intangible asset		16			–				(4,063,000	)
Other expenses		16			(111,423	)			(31,918	)
Change in fair value of investment properties		16			(44,079	)			–
Operating loss					(5,207,263	)			(7,681,603	)
Finance cost		16			(865,273	)			(367,270	)
Net loss on convertible notes designated at FVTPL		12			(2,617,807	)			–
Net gain on warrant liabilities		12			1,726,802				(24,075	)
Loss before tax					(6,963,541	)			(8,072,948	)
Income tax expenses		17			(99,272	)			(123,038	)
Loss for the period					(7,062,813	)			(8,195,986	)
Other comprehensive (loss) income
Foreign currency translation differences – foreign operations					(817,032	)			290,378
Change in fair value of convertible notes designated at FVTPL due to own credit risk					1,726				–
Total comprehensive loss for the period					(7,878,119	)			(7,905,608	)
Loss attributable to:
Equity owners of the Company					(7,170,893	)			(8,246,755	)
Non-controlling interests					108,080				50,769
Loss for the period					(7,062,813	)			(8,195,986	)
Total comprehensive loss attributable to:
Equity owners of the Company					(7,980,794	)			(7,963,848	)
Non-controlling interests					102,675				58,240
Total comprehensive loss for the period					(7,878,119	)			(7,905,608	)
Basic loss per share*		15			(13.62	)			(311.00	)
Diluted loss per share*		15			(13.62	)			(311.00	)
Weighted average number of shares
Basic					526,603				26,517
Diluted					526,603				26,517

*

The shares and per share information are presented on a retroactive basis to reflect the reorganization. Further, the Class A ordinary shares are presented on a retroactive basis to reflect the Company’s reverse share split of 50-for-1 on March 23, 2026 and 30-for-1 on June 23, 2026, respectively.